Antimalarial activity of tigecycline, a novel glycylcycline antibiotic.
Tigecycline is a novel glycylcycline antibiotic with a broad antibacterial spectrum. Tigecycline was tested with 66 clinical isolates of Plasmodium falciparum from Bangladesh using the histidine-rich protein 2 in vitro drug susceptibility assay. The 50% and 90% inhibitory concentrations of tigecycline were 699 (95% confidence interval, 496 to 986) and 5,905 nM (4,344 to 8,028). Tigecycline shows no activity correlation with traditional antimalarials and has substantial antimalarial activity on its own.
Starzengruber
P
P
Department of Specific Prophylaxis and Tropical Medicine, Medical University of Vienna, Vienna, Austria.
Thriemer
K
K
Haque
R
R
Khan
W A
WA
Fuehrer
H P
HP
Siedl
A
A
Hofecker
V
V
Ley
B
B
Wernsdorfer
W H
WH
Noedl
H
H
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000962:Antimalarials / Q000494:pharmacology*; D004318:Doxycycline / Q000494:pharmacology; D020128:Inhibitory Concentration 50; D008911:Minocycline / Q000031:analogs & derivatives* / Q000494:pharmacology; D021261:Parasitic Sensitivity Tests; D010963:Plasmodium falciparum / Q000187:drug effects*; D013752:Tetracycline / Q000494:pharmacology; D013754:Tetracyclines / Q000494:pharmacology*; D000078304:Tigecycline
D000900:Anti-Bacterial Agents; D000962:Antimalarials; D013754:Tetracyclines; C087533:CL 331002; D000078304:Tigecycline; D013752:Tetracycline; D008911:Minocycline; D004318:Doxycycline